3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
2
Cardiotoxicity
2
Weight Gain
1
Renal Insufficiency, Chronic
1
Neoplasms
1
Kidney Neoplasms
1
Heart Failure
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Sunitinib
26
Everolimus
20
Bevacizumab
19
aldesleukin
18
Sorafenib
16
Nivolumab
16
Interleukin-2
14
pembrolizumab
13
Peripheral Blood Stem Cell Transplantation
13
fludarabine phosphate
12
Radiotherapy
12
Interferon-alpha
12
Cyclophosphamide
12
Radiosurgery
11
Filgrastim
11
Blood Specimen Collection
11
Ipilimumab
10
Gemcitabine
10
Axitinib
9
Surveys and Questionnaires
7
Gene Expression Profiling
7
Cryosurgery
7
temsirolimus
6
pazopanib
6
Surgical Procedures, Operative
6
durvalumab
5
cabozantinib
5
atezolizumab
5
Mycophenolic Acid
5
Immunohistochemistry
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Neoplasms
×
empagliflozin
×
Clear all
NCT06818305
2025-12-11
EmFin-Nx
Jinling Hospital, China
Phase 2
Terminated
10 enrolled